Now Is The Time To Build A Position In Citius Oncology Inc (NASDAQ:CTOR)

Citius Oncology Inc (NASDAQ:CTOR) has a beta value of 0.30 and has seen 69.9 million shares traded in the last trading session. The company, currently valued at $66.54M, closed the last trade at $0.93 per share which meant it gained $0.26 on the day or 39.85% during that session. The CTOR stock price is -5168.82% off its 52-week high price of $49.00 and 40.86% above the 52-week low of $0.55. If we look at the company’s 10-day average daily trading volume, we find that it stood at 7.28 million shares traded. The 3-month trading volume is 128.15K shares.

Citius Oncology Inc (NASDAQ:CTOR) trade information

Sporting 39.85% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CTOR stock price touched $0.93 or saw a rise of 20.51%. Year-to-date, Citius Oncology Inc shares have moved -19.13%, while the 5-day performance has seen it change 30.99%. Over the past 30 days, the shares of Citius Oncology Inc (NASDAQ:CTOR) have changed -21.85%. Short interest in the company has seen 27881.0 shares shorted with days to cover at 0.54.

Citius Oncology Inc (CTOR) estimates and forecasts

The company’s shares have lost -34.97% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.

1 analysts offering their estimates for the company have set an average revenue estimate of 5.74M for the current quarter. 1 have an estimated revenue figure of 8.6M for the next ending quarter.

CTOR Dividends

Citius Oncology Inc is expected to release its next earnings report on 2025-Feb-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Citius Oncology Inc (NASDAQ:CTOR)’s Major holders

Insiders own 95.08% of the company shares, while shares held by institutions stand at 0.89% with a share float percentage of 18.10%. Investors are also buoyed by the number of investors in a company, with Citius Oncology Inc having a total of 14.0 institutions that hold shares in the company.